Conversation Series | Meet The Expert – Professor Eric Chung
The first episode of the LTR Pharma Conversation Series is now live. This week, we introduce to you Professor Eric Chung, LTR Pharma Scientific and
LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
The first episode of the LTR Pharma Conversation Series is now live. This week, we introduce to you Professor Eric Chung, LTR Pharma Scientific and
LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung shares insights with Body + Soul to discuss the correlation between performance
LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung was recently interviewed by Cayle Reid at Men’s Health Australia to discuss
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711